You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Rapid Multiplexed Assay for the Diagnosis of Viral Hepatitis at the Point of Care
SBC: INSTADIAGNOSTICS INC Topic: CDCProject Summary/Abstract: Instadiagnostics (IDI) is developing a point-of-care (POC) diagnostic technology platform with the goal of providing early detection, screening, and treatment monitoring for patients at primary care centers, community clinics, urgent care centers, and emergency departments. The device consists of a portable reader (the InstaReader) and disposable cartridges (InstaCartridg ...
SBIR Phase II 2020 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
SBC: Axonova Medical LLC Topic: 106PROJECT SUMMARY Tissue engineered medical products have tremendous promise to address the currently irreparable effects of neurotrauma and/or neurodegenerative diseases. Axonova Medical’s lead product, the tissue engineered nerve graft (TENG), is a bioactive “living scaffold” proven to promote rapid nerve regeneration and functional restoration when implanted to repair major peripheral nerve ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel Expandable Infusion Catheter for the Treatment of Acute Pulmonary Embolism
SBC: THROMBOLEX, INC. Topic: NHLBIPROJECT SUMMARY—Thrombolex, Inc. has developed an intravascular catheter with an expandable spiral basket of infusion limbs to improve the efficacy of catheter-directed thrombolysis (CDT) in large vessels. Preclinical studies indicate administration of recombinant tissue plasminogen activator (rtPA) via the Bashir™ Endovascular Catheter (BEC) reduces thrombus burden to a greater degree than no ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Nutritional Stimulation of Muscle Protein Synthesis and Metabolic Rate After Bariatric Surgery
SBC: THE AMINO COMPANY LLC Topic: 3007. Project Summary/Abstract Bariatric surgery has become a common treatment for severe obesity. While this results in the desired loss of fat mass, muscle mass is also lost with implications for post-surgical health benefits. It is our overarching premise that consumption of our essential amino acid (EAA)-based nutritional formulation following bariatric surgery will preserve muscle mass by stimul ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array
SBC: INTEGRAL MOLECULAR INC Topic: 400ABSTRACT Detailed specificity analysis is critical for drugs, as even minimal off-target binding can cause serious adverse events. As a result, specificity profiling has become an FDA requirement for monoclonal antibodies (MAbs) as well as other emerging biotherapeutic categories such as CAR-T cell therapy. Current methods for profiling the specificity of biotherapeutics, primarily tissue cross-re ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
SBC: INTEGRAL MOLECULAR INC Topic: 400ABSTRACT T cell-mediated autoimmune and chronic inflammatory diseases affect 23 million Americans, corresponding to ~$100B/year in direct healthcare costs. Pharmaceutical advances have enabled the development of treatments for these diseases, but existing drugs have severe immune- compromising side effects because they broadly target all T cell activity. The voltage-gated ion channel Kv1.3 is a va ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
MyHealthyPregnancy mobile health app: Combining behavioral science and machine learning for risk communication during the peripartum period
SBC: Naima Health LLC Topic: NCCDPHPABSTRACT: Depression during pregnancy affects approximately 10% of women and is related to low birthweight and preterm birth. Similarly, up to 9% of pregnant women experience intimate partner violence (IPV) and abuse, with over 41% of assaults resulting in physical injury, and almost 30% requiring medical treatment. When untreated, these risks cost health systems at least $50B/year. Mitigation has ...
SBIR Phase II 2020 Department of Health and Human ServicesCenters for Disease Control and Prevention -
IMPROVEMENT TO OZONATING WATER FOR POST-HARVEST WASHING THROUGH NANOBUBBLES
SBC: En Solucion Inc Topic: FDAAbstract. As consumer demand for fresh produce continues to grow, so do concerns by the Food and Drug Administration (FDA) about foodborne illnesses and foodborne disease outbreaks. Postharvest wash is a critical control point in fresh produce processing for reducing or eliminating pathogens and other field-acquired contaminants that can result in such outbreaks. Current methods of post-harvest wa ...
SBIR Phase II 2020 Department of Health and Human ServicesFood and Drug Administration -
Microelectrode Array Insertion System using Ultrasonic Vibration to Improve Insertion Mechanics, Reduce Tissue Dimpling and Trauma, and Improve Placement Precision in the Neocortex
SBC: ACTUATED MEDICAL, INC. Topic: NINDSThis Phase II SBIR further develops and tests a system that employs ultrasonic vibration to improve the insertion mechanics for multichannel penetrating electrode arrays. This proposal is in response to PA-18-871 BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research – including ‘Iterative refinement of such tools and technologies ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Advancing SRX246 to Commericialization
SBC: Azevan Pharmaceuticals Inc Topic: 106PROJECT SUMMARY/ABSTRACTSRX246, a first-in-class, orally bioavailable, CNS-active vasopressin 1a receptor antagonist, recently was tested in an Exploratory Phase 2 clinical trial, “Safety, Tolerability, and Activity of SRX246 in Irritable Subjects with Huntingtonandapos;s Disease (STAIR),” with support from an SBIR Fast Track award (5U44NS090616). The trial, conducted in collaboration with the ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health